TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: heart rate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cuff leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microaspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Robotic limb position matching standardized score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Robotic kinaesthesia standardized score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days of Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spike-Wave Index (SWI) on EEG during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chloroquine serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR)/complete response with incomplete bone marrow recovery (CRi) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete response rate of the combination regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CR + marrow CR (mCR) + partial remission (PR) + hematological improvement (HI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of nosocomial pneumopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Upper Extremity Fugl-Meyer Assessment (UE-FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II dose
Endpoint domain: Resource use
Primary endpoint: Clinical performance by Oxford scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine 15-F2t Isoprostane Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients presenting a neuro-ophthalmological abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fusion at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of delayed recall name-phase association test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Completing HCV Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Attaining SVR12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sonographic detection rate of clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ketamine (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State (Css)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half Life (T1/2) for Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation of Levels of Total Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modulation of Deoxygenated Levels of Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive training performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Suitability and acceptability of study method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug Liking VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Female Sexual Function Index (FSFI) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of effective closure of the ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patellar length to patellar tendon length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patellar articular surface length to patella-tibial plateau distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants with Adverse Events of Interest (AEIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean platelet glycoprotein sialyation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients having persistent pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Time of Maximal Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Time Concentration Curve [AUC(0-24h)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urinary concentrations of prostacycline (PGI2) and thromboxane A2 (TxA2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anterior knee pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of nCLE images of lung nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP reduction over 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hemostatic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of Participants With ppIGA 0 or 1 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of 2 cycles of induction paclitaxel/carboplatin/irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With at Least One Occurrence of Safety Composite Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: any cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change of maximum clot firmness (MCF) of FIBTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Clotting time (CT) of INTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Clot firmness time (CFT) of INTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glycosylated hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of CVX-045
Endpoint domain: Adverse events/effects
Primary endpoint: CVX-045-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Goal Attainment Scaling Leg T score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure biofeedback measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laser tracking measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Medically-attended Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Donor blood transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in auditory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain relaxation at the opening of the dura mater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: T-lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of patients with testosterone at or below chemical castration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Disinfecting Barrier Cap Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Scrub the Hub Protocol Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: allele frequency of CMT genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genotype frequency of CMT genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Class attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Partial score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fMRI blood-oxygen-level-dependent (BOLD) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromechanical delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-time Curve of Caffeine in Plasma (AUC0-infinity, Caffeine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Caffeine in Plasma (Cmax, Caffeine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of S-warfarin in Plasma (AUC0-infinity, S-warfarin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of S-warfarin in Plasma (Cmax, S-warfarin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urine Na / K ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Short Musculoskeletal Function Assessment (SMFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Validity of home sleep study device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Within-day glucose variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self reported reduction in average cigarettes smoked per day at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported reduction in average cigarettes smoked per day at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bacterial Count on the Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with plasma HIV-1 RNA <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pre-dialysis serum bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Continuation rate of PPIUCD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Nicotine Concentration in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Carboxyhemoglobin in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Urine in 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of 3-hydroxypropylmercapturic Acid in Urine in 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of S-phenyl Mercapturic Acid in Urine in 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PED/PEA-15 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Febrile malaria episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma 25-hydroxy vitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Parasite Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 28-day Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative liver injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: washout time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular events incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of stay hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Increase in PLL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsidence of Excia T® stem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central point thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean Leg Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-INF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of FVIII inhibitors
Endpoint domain: Adverse events/effects
Primary endpoint: Bond and Lader visual analogue scale (BL VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: All causes of morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pruritus as Assessed by the VAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle phenylalanine net balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Reported a Suicide Event
Endpoint domain: Adverse events/effects
Primary endpoint: Dental caries measured by DMFT index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour IOP fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 24-hour blood pressure pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Achieving Clinical Remission at Week 56 (NRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Clinical Remission at Week 56 (LOCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ventricular thrombosis or silent brain infarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Well-controlled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving a 20% or Greater Reduction in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in IOP From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with a post-operative wound complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ADOS-2 scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in SBIS-5 scores or Mullen Scales of Early Learning (MSEL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Fractional anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose metabolism in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Plasma Glucose <126 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PAAL (Postoperative Acute Lung Injury)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of children achieving spasm freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale (HAMD-17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of de-identification of PII
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical patient status according to Harris Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal (peak) oxidative capacity (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of cT1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment Emergent (TE) Serious Adverse Events (SAEs) and Non-SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With TEAEs Leading to Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician Administered PTSD Scale (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PTSD Checklist
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of state of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement of general anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Patient Satisfaction with Eyelashes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mediterranean diet score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Taste Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal chromosome abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics measured by Cmax and AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Hematological Response of Complete Remission or Complete Remission With Partial Hematological Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Freedom from documented AF episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aberdeen Low Back Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Roland-Morris Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Mean Systolic Blood Pressure at Visit 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean Systolic Blood Pressure at Visit 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adhesion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spatiotemporal variables in meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spatiotemporal variables in percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kinematic parameters in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Knee Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspired minimum CO2 (imCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine Fibroid Symptom Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ruta Menorrhagia (Bleeding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average diurnal intra-ocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Daily Active Minutes of Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes